This new level of transparency will make harmful or counterfeit prescription drugs more visible in the supply chain, and thus make it possible to remove them before they reach the consumer.
Staffan Widengren, director corporate projects at Recipharm, spoke to World Pharma Today on the difficulty of implementing new serialisation processes with only six months left to go, and gives advice to manufacturers who are behind in their preparations.